Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma (LOTIS-6)

A Phase 2 Randomized Study of Loncastuximab Tesirine Versus Idelalisib in Patients With Relapsed or Refractory Follicular Lymphoma (LOTIS-6)

This study aims to evaluate the efficacy of single agent loncastuximab tesirine compared to idelalisib in participants with relapsed or refractory follicular lymphoma.

Study Overview

• Status: Terminated
• Conditions: Relapsed Follicular Lymphoma; Refractory Follicular Lymphoma
• Intervention / Treatment: Drug: Loncastuximab Tesirine; Drug: Idelalisib

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 2

Contacts and Locations

Study Locations

• Belgium
  • Gent, Belgium, 9000
    • Universitair Ziekenhuis Gent
  • Yvoir, Belgium, B-5530
    • Centre Hospitalier Universitaire Universite Catholique de Louvain
• France
  • Dunkerque, France, 59385
    • Centre Hospitalier de Dunkerque
  • La Rochelle, France, 17000
    • Centre Hospitalier de La Rochelle
  • Rouen, France, 76038
    • Centre de Lutte Contre le Cancer - Centre Henri-Becquerel
  • Tours Cedex 9, France, 37044
    • Hôpital Bretonneau
• Hungary
  • Budapest, Hungary, 1122
    • Orszagos Onkologiai Intezet
  • Budapest, Hungary, 1088
    • Semmelweis Egyetem
  • Pécs, Hungary, 7624
    • Pécsi Tudományegyetem Klinikai Központ
• Israel
  • Be'er Sheva, Israel, 8410101
    • Soroka Medical Center
  • Haifa, Israel, 3436212
    • Carmel Medical Center
  • Petah tikva, Israel, 4941492
    • Rabin Medical Center - Beilinson Hospital
  • Tel Aviv, Israel, 6423906
    • Tel Aviv Sourasky Medical Center
  • Tel Aviv, Israel, 52621
    • The Chaim Sheba Medical Center
• Italy
  • Firenze, Italy, 50134
    • Azienda Ospedaliero - Universitaria Careggi
• Poland
  • Gdynia, Poland, 81-519
    • Szpitale Pomorskie Spółka Z Ograniczoną Odpowiedzialnością
  • Katowice, Poland, 40-519
    • Pratia Onkologia Katowice
  • Skorzewo, Poland, 60-185
    • Pratia Poznan
• Spain
  • L'Hospitalet De Llobregat, Spain, 08908
    • Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)
  • Lleida, Spain, 25198
    • Hospital Universitari Arnau de Vilanova
  • Madrid, Spain, 28040
    • Hospital Universitario Fundacion Jimenez Diaz
  • Madrid, Spain, 28046
    • Hospital Universitario La Paz
  • Madrid, Spain, 28007
    • Hospital General Universitario Gregorio Maranon
  • Madrid, Spain, 08908
    • Hospital Universitario Ramon y Cajal
  • Pozuelo De Alarcón, Spain, 28223
    • Hospital Universitario Quironsalud Madrid
  • Sevilla, Spain, 41013
    • Hospital Universitario Virgen del Rocio
• Switzerland
  • Bern, Switzerland, 3010
    • INSELSPITAL Universitatsspital Bern
• United Kingdom
  • Glasgow, United Kingdom, G51 4TF
    • NHS Greater Glasgow and Clyde
  • London, United Kingdom, NW1 2PG
    • Account University College London Hospitals NHS Foundation Trust
• United States
  • Nevada
    • Las Vegas, Nevada, United States, 89169
      • Comprehensive Cancer Centers of Nevada
    • Las Vegas, Nevada, United States, 89074
      • Comprehensive Cancer Centers of Nevada - Central Valley
  • New Jersey
    • Florham Park, New Jersey, United States, 07932
      • Summit Medical Group - Florham Park Campus
    • Florham Park, New Jersey, United States, 07932
      • Summit Medical Group
  • South Carolina
    • Charleston, South Carolina, United States, 29425
      • Hollings Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Written informed consent must be obtained prior to any study procedures.
• Male or female participants aged 18 years or older, with pathologic diagnosis of follicular lymphoma (FL) (Grade 1, 2, 3A) in the most recent tumor biopsy.
• Relapsed or refractory disease following two or more treatment regimens, at least one of which must have contained an anti-CD20 therapy.
• Participants who have received previous CD19-directed therapy must have a biopsy which shows CD19 expression after completion of the CD19-directed therapy.
• Measurable disease as defined by the 2014 Lugano Classification as assessed by positron emission tomography - computed tomography (PET-CT) or, if not Fluorodeoxyglucose (FDG) avid, CT or magnetic resonance imaging (MRI).
• Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block (or minimum 10 freshly cut unstained slides if block is not available). Note: Any biopsy since initial diagnosis is acceptable, but if several samples are available, the most recent sample is preferred.
• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

• Adequate organ function as defined by screening laboratory values within the following parameters:

  1. Absolute neutrophil count (ANC) ≥1.0 × 10^3/μL (off growth factors at least 72 hours),
  2. Platelet count ≥75 × 10^3/μL without transfusion in the past 2 weeks,
  3. Alanine aminotransferase, AST, and GGT ≤2.5 × the upper limit of normal (ULN),
  4. Total bilirubin ≤1.5 × ULN (participants with known Gilbert's syndrome may have a total bilirubin up to ≤3 × ULN),
  5. Calculated creatinine clearance ≥30 mL/min by the Cockcroft and Gault equation. Note: A laboratory assessment may be repeated a maximum of two times during the Screening period to confirm eligibility

• Women of childbearing potential (WOCBP)(1) must agree to use a highly effective method(2) of contraception from the time of giving informed consent until at least 9 months after the last dose of study treatment. Men with female partners who are of childbearing potential must agree to use a condom when sexually active or practice total abstinence from the time of giving informed consent until at least 6 months after the participant receives his last dose of study treatment.

  1. WOCBP are defined as sexually mature women who have not undergone bilateral tubal ligation, bilateral oophorectomy, or hysterectomy; or who have not been postmenopausal. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
  2. Highly effective forms of birth control are methods that achieve a failure rate of less than 1% per year when used consistently and correctly. Highly effective forms of birth control include hormonal contraceptives associated with inhibition of ovulation (oral, injectable, patch, intrauterine devices), male partner sterilization, or total abstinence from heterosexual intercourse, when this is the preferred and usual lifestyle of the participant.

Note: The double-barrier method (e.g., synthetic condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel), periodic abstinence (such as calendar, symptothermal, post ovulation), withdrawal (coitus interruptus), lactational amenorrhea method, and spermicide-only are not acceptable as highly effective methods of contraception.

Exclusion Criteria:

• Previous treatment with loncastuximab tesirine.
• Previous treatment with idelalisib.
• History of hypersensitivity to any of the excipients of loncastuximab tesirine or idelalisib.
• Follicular lymphoma which has transformed to diffuse large B-cell lymphoma (DLBCL) or other aggressive lymphomas.
• Requires treatment or prophylaxis with a strong cytochrome P450 (CYP) 3A inhibitor, inducer, or sensitive substrate.
• History of or ongoing drug-induced pneumonitis.
• History of or ongoing inflammatory bowel disease.
• Any condition that could interfere with the absorption or metabolism of idelalisib including malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.
• Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that the Sponsor's medical monitor and Investigator agree and document should not be exclusionary.
• Autologous transplant within 30 days prior to start of study treatment (C1D1).
• Allogenic transplant within 60 days prior to start of study treatment (C1D1).
• Active graft-versus-host disease.
• Post-transplantation lymphoproliferative disorders.

• Human immunodeficiency virus (HIV) seropositive with any of the following:

  1. CD4+ T-cell counts <350 cells/μL.
  2. Acquired immuno-deficiency syndrome (AIDS)-defining opportunistic infection within 12 months prior to screening.
  3. Not on anti-retroviral therapy, or on anti-retroviral therapy for < 4 weeks at the time of screening.
  4. HIV viral load ≥400 copies/mL.
• Serologic evidence of chronic hepatitis B infection and unable or unwilling to receive standard prophylactic anti-viral therapy or with detectable hepatitis B virus (HBV) viral load.
• Serologic evidence of hepatitis C infection without completion of curative treatment or with detectable hepatitis C virus (HCV) viral load.
• History of Stevens-Johnson syndrome or toxic epidermal necrolysis.
• Lymphoma with active central nervous system involvement, including leptomeningeal disease.
• Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath).
• Breastfeeding or pregnant.
• Significant medical comorbidities, including but not limited to, uncontrolled hypertension (BP ≥160/100 mm Hg repeatedly), unstable angina, congestive heart failure (greater than New York Heart Association class II), electrocardiographic evidence of acute ischemia, coronary angioplasty or myocardial infarction within 6 months prior to screening, uncontrolled atrial or ventricular cardiac arrhythmia, poorly controlled diabetes, or severe chronic pulmonary disease.
• Any Grade ≥3 active infection which requires IV antibiotics, IV antiviral, or IV antifungal treatment.
• Major surgery, radiotherapy, chemotherapy or other anti-neoplastic therapy within 14 days prior to start of study treatment (C1D1), except shorter if approved by the Sponsor.
• Use of any other experimental medication within 30 days prior to start of study treatment (C1D1).
• Live vaccine administration within 4 weeks prior to Cycle(C) 1 Day (D) 1.
• Failure to recover to ≤ Grade 1 (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) from acute non-hematologic toxicity (except ≤Grade 2 neuropathy or alopecia) due to previous therapy prior to screening.
• Any other significant medical illness, abnormality, or condition that would, in the Investigator's judgment, make the participant inappropriate for study participation or put the participant at risk.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Loncastuximab Tesirine; Participants will be administered loncastuximab tesirine as an intravenous (IV) infusion on Day 1 of each cycle, where 1 cycle is 3 weeks. Loncastuximab tesirine will be administered at a dose of 150 μg/kg for 2 cycles, then at a dose of 75 μg/kg for subsequent cycles.	Drug: Loncastuximab Tesirine; IV infusion; Other Names: Zynlonta; ADCT-402
Active Comparator: Idelalisib; Participants will be administered 150 mg idelalisib, orally, twice a day throughout each cycle, where 1 cycle is 4 weeks.	Drug: Idelalisib; Oral tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete Response Rate (CRR)	CRR was defined as the percentage of participants who experienced a best overall response (BOR) of complete response (CR) assessed prior to any subsequent anticancer treatment.	Up to the end of treatment, maximum time on treatment was 333 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response Rate (ORR)	ORR was defined as the percentage of participants with a BOR of CR or partial response (PR) assessed prior to any subsequent anticancer treatment.	Up to end of treatment, maximum time on treatment was 333 days
Progression-Free Survival (PFS)	PFS was defined as the time between the randomization date and the first documentation of recurrence, progression, or death.	Up to end of treatment, maximum time on treatment was 333 days
Overall Survival (OS)	OS was defined as the time between the randomization date and death from any cause.	Up to end of treatment, maximum time on treatment was 333 days
Duration of Response (DOR)	DOR was defined as the time from the documentation of tumor response to disease progression or death.	Up to end of treatment, maximum time on treatment was 333 days
Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)	TEAEs were defined as an AE that occurs or worsens in the period extending from the first dose of study treatment until 30 days after the last dose of study treatment or start of new anti-cancer therapy, whichever is earlier. Any clinically significant changes from baseline in the safety laboratory values, vital signs, 12-lead electrocardiogram (ECG), and Eastern Cooperative Oncology Group (ECOG) performance status were reported as TEAEs.	Day 1 to 30 days after end of treatment, maximum time on treatment was 333 days
Average Concentration of Loncastuximab Tesirine Before Infusion		Up to end of treatment, maximum time on treatment was 333 days
Average Concentration of Loncastuximab Tesirine at the End of Infusion		Up to end of treatment, maximum time on treatment was 333 days
Clearance Rate of Loncastuximab Tesirine		Up to end of treatment, maximum time on treatment was 333 days
Volume of Distribution of Loncastuximab Tesirine		Up to end of treatment, maximum time on treatment was 333 days
Number of Participants With Anti-Drug Antibody (ADA) Titers to Loncastuximab Tesirine		Up to end of treatment, maximum time on treatment was 333 days
Change From Baseline in Health-Related Quality of Life (HRQoL) as Measured by the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)		Up to end of treatment, maximum time on treatment was 333 days
Change From Baseline in Health-Related Quality of Life (HRQoL) as Measured by the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)		Up to end of treatment, maximum time on treatment was 333 days
Number of Participants With Specific Symptomatic Adverse Event Symptoms As Selected From Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)	The specific symptomatic adverse events includes fatigue, swelling, rash, nausea, diarrhea, abdominal pain, and cough.	Up to end of treatment, maximum time on treatment was 333 days
Treatment-Related Symptoms as Assessed by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)	The specific symptoms assessed include fatigue, swelling, rash, nausea, diarrhea, abdominal pain, and cough. The severity is assessed from "None" to "Very severe" and the interference level is assessed from "Not at all" to "Very much."	Up to end of treatment, maximum time on treatment was 333 days

Collaborators and Investigators

• Sponsor: ADC Therapeutics S.A.

Study record dates

Study Major Dates

• Study Start (Actual): November 4, 2021
• Primary Completion (Actual): November 25, 2022
• Study Completion (Actual): November 25, 2022

Study Registration Dates

• First Submitted: January 5, 2021
• First Submitted That Met QC Criteria: January 5, 2021
• First Posted (Actual): January 7, 2021

Study Record Updates

• Last Update Posted (Actual): October 23, 2023
• Last Update Submitted That Met QC Criteria: September 28, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: Lymphoma; Follicular Lymphoma; Loncastuximab Tesirine; Relapsed Follicular Lymphoma; Refractory Follicular Lymphoma
• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, Follicular; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Immunological; Idelalisib; Loncastuximab tesirine
• Other Study ID Numbers: ADCT 402-202; 2020-003695-40 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No